ExAdEx NAM organoids to reduce animal experimentation
Organoid models developed by ExAdEx-Innov and collaborators presented at the 3R LÄND CONFERENCE 2024 in Tübingen (Germany) Latest work from ExAdEx-Innov team on clinically relevant
Exsymol is a leader in the conception of active ingredients for cosmetics and nutrition for more than 45 years, including Silanols, Exsymol’s signature technology: a unique and innovative family of cosmetic actives with a heart of organic silicium.
The collaboration between Exsymol and ExAdEx-Innov has led to innovative results on CAFEISILANE, an active ingredient combining caffeine and biofunctional silicon core, from the well-known range derived from silanols, on our ExAdEx models of fibro-inflammation of adipose tissue. This marks a significant milestone in the development of Exsymol’s cosmetic active ingredients, using relevant ex vivo models.
« The work performed in collaboration with Exsymol’s team is a major event for our company, demonstrating how our solution can finally fill the gap that has been existing in cosmetic research on human adipose tissue for years. We are thrilled to work with developers as Exsymol for the development of cosmetic active ingredients based on our highly innovative ExAdEx models and know-how« , says Vincent Dani, President and co-founder of ExAdEx-Innov.
Exsymol website page: www.exsymol.com
ExAdEx research platform: www.exadex-innov/exadex-platform
Organoid models developed by ExAdEx-Innov and collaborators presented at the 3R LÄND CONFERENCE 2024 in Tübingen (Germany) Latest work from ExAdEx-Innov team on clinically relevant
Scientific work performed by ExAdEx-Innov researchers and collaborators will be presented during European Congress on Obesity ECO 2024 Latest work on adipose tissue and obesity
ExAdEx-Innov has received approval from the French Ministry of Research as a service provider eligible to French Research Tax Credit (Agrément CIR, Crédit Impôt Recherche)
Copyright © 2022 ExAdEx-Innov All rights reserved
KOL on adipose tissue biology.
Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice).
Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program).
Co-inventor of 5 patents
Expert in clinical applications of adipose tissue.
Plastic Reconstructive and Aesthetic Surgeon in Nice.
Member of the Medical Council of Alpes Maritimes region.
Expert for the French National Regulatory Agency ANSM for medical devices.
Certified by French Health Autority HAS (2020-2024).
PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.
Expert in cell therapy and immunology.
Senior Lecturer (Maitre de conférences).
Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).
Director of « Micoralis » research team at Université Côte d’Azur (Nice).
Founder and CEO of the biotech company Biointerférence (2003-2006).
Co-inventor of 5 patents.
Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.
With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov.
In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille).
He is co-inventor of the 2 company’s patent families.
Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue.
Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.
With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years.
He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.
Main areas of expertise: Biotech Startup Business Development; Project management